 |
|
|
| |
Safety and Antiviral Activity of ABT-267, a Novel NS5A Inhibitor, During 3-Day Monotherapy:
First Study in HCV Genotype-1 (GT1)-Infected Treatment-Naïve Subjects
|
| |
| |
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Eric Lawitz1, Thomas Marbury2, Andrew Campbell3, Emily Dumas3, Tami Pilot-Matias3, Preethi Krishnan3, Carolyn Setze3, Wangang Xie3, Thomas Podsadecki3, Barry Bernstein3, Laura Williams3
1Alamo Medical Research, San Antonio, Texas, United States; 2Orlando Clinical Research Center, Orlando, Florida, United States; 3Abbott, Abbott Park, Illinois, United States
|
| |
|
|
|
|
|
